United Therapeutics (UTHR) director 10b5-1 option exercise, sale

Rhea-AI Filing Summary

United Therapeutics Corporation director Christopher Causey reported an option exercise and share sale. On January 6, 2026, he exercised stock options for 1,000 shares of common stock at an exercise price of $119.76 per share and acquired the underlying shares.

On the same date, he sold 1,000 shares of United Therapeutics common stock at a reported price of $510 per share. After these transactions, he directly owned 4,190 shares of common stock and 7,320 stock options. The filing notes that the option exercise and sale were carried out under a Rule 10b5-1 trading plan adopted on September 30, 2025.

Insider Trade Summary

Net Seller: 1,000 shares ($510,000)

Net Sell 3 txns

Insider CAUSEY CHRISTOPHER

Role Director

Sold 1,000 shs ($510K)

Type	Security	Shares	Price	Value
Exercise	Stock Option	1,000	$0.00	--
Exercise	Common Stock	1,000	$119.76	$120K
Sale	Common Stock	1,000	$510.00	$510K

Holdings After Transaction: Stock Option — 7,320 shares (Direct); Common Stock — 5,190 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAUSEY CHRISTOPHER

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		M(1)		1,000	A	$119.76	5,190	D
Common Stock	01/06/2026		S(1)		1,000	D	$510	4,190	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$119.76	01/06/2026		M(1)			1,000	06/26/2021	06/26/2030	Common Stock	1,000	$0.00	7,320	D

Explanation of Responses:

1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 30, 2025.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did United Therapeutics (UTHR) report in this Form 4?

Director Christopher Causey reported exercising 1,000 stock options for United Therapeutics common stock and selling 1,000 shares of common stock on January 6, 2026.

At what prices did Christopher Causey exercise and sell United Therapeutics (UTHR) shares?

He exercised stock options at an exercise price of $119.76 per share and reported selling 1,000 shares of common stock at a price of $510 per share.

How many United Therapeutics (UTHR) shares does Christopher Causey own after these transactions?

Following the reported transactions, Christopher Causey directly owned 4,190 shares of United Therapeutics common stock and held 7,320 stock options.

Was the United Therapeutics (UTHR) insider trade made under a Rule 10b5-1 plan?

Yes. The filing states that the stock option exercise and subsequent sale of shares were made pursuant to a Rule 10b5-1 trading plan that Christopher Causey entered into on September 30, 2025.

What is Christopher Causey’s relationship to United Therapeutics (UTHR)?

Christopher Causey is reported as a director of United Therapeutics Corporation and is not listed as an officer or 10% owner in this filing.

Is this United Therapeutics (UTHR) Form 4 filed by more than one reporting person?

No. The document indicates that the Form 4 was filed by one reporting person, namely director Christopher Causey.